so in short,
- not approved
- SPL will review if they can 1) appeal, 2) pursue legal options or 3) conduct another trial.
- they will assess which of the above options is the fastest path
I think we can safely say SPL will not have access to the US for another 1-2 years.
The convoluted announcements on vivagel in the US detract from managements credibility. I know it's not easy, but just be clear.
note, I remain very positive on SPL with many important milestones to come. revenue from Europe to start soon and the main prize has always been Dep.
Ann: Regulatory progress for VivaGel BV in the US, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.002(2.00%) |
Mkt cap ! $40.98M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $3.09K | 30.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16397 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 24393 | 1 |
View Market Depth
| Last trade - 15.32pm 11/07/2025 (20 minute delay) ? |
| SPL (ASX) Chart |